Arrowhead Pharma (ARWR) Stock
Fundamentals
Recent news

Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress
Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress
ARWR

Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands
Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands
ARWR

Not A ‘Gangbusters Launch’ — Arrowhead Predicts Slow Burn to $3B-$4B Peak For Redemplo, Highlights ‘Massive Pipeline’
Not A ‘Gangbusters Launch’ — Arrowhead Predicts Slow Burn to $3B-$4B Peak For Redemplo, Highlights ‘Massive Pipeline’
ARWR

ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data — Is This A ‘Sell The News’ Move?
ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data — Is This A ‘Sell The News’ Move?
ARWR
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$1.22 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress
Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress
ARWR

Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands
Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands
ARWR

Not A ‘Gangbusters Launch’ — Arrowhead Predicts Slow Burn to $3B-$4B Peak For Redemplo, Highlights ‘Massive Pipeline’
Not A ‘Gangbusters Launch’ — Arrowhead Predicts Slow Burn to $3B-$4B Peak For Redemplo, Highlights ‘Massive Pipeline’
ARWR

ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data — Is This A ‘Sell The News’ Move?
ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data — Is This A ‘Sell The News’ Move?
ARWR

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
ARWR

Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million
ARWR

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
ARWR

Arrowhead's Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials
Arrowhead's Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials
ARWR

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
ARWR

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
ARWR
About Arrowhead Pharma
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Christopher R. Anzalone Ph.D. | Chairman, CEO & President | 1969 |
| Mr. Daniel J. Apel | Chief Financial Officer | 1966 |
| Mr. Patrick O'Brien J.D., PharmD | COO & Secretary | 1964 |
| Dr. James C. Hamilton M.D., MBA | Chief Medical Officer and Head of R&D | 1979 |
| Dr. Mark M. Davis Ph.D. | Founder and Founder & Director of Insert Therapeutics Inc & Calando | — |
| Dr. Tao Pei Ph.D. | Chief Scientific Officer | — |
| Dr. Vincent Anzalone CFA | Head of Investor Relations & VP | — |
| Mr. Howard Lovy | Director of Communications | — |
| Dr. Bruce D. Given M.D. | Chief Medical Scientist | 1954 |
| Dr. Mark Seefeld | Head of Toxicology & VP | 1954 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
10 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +3.0 | +1.9 | -1.3 | -1.0 | ||||||||
| 2022 | -24.6 | -20.1 | +3.8 | -16.4 | -22.5 | +6.5 | +18.3 | -4.9 | -20.0 | +3.2 | -9.3 | +26.7 |
| 2023 | -9.1 | -8.5 | -22.2 | +38.5 | -3.7 | +2.9 | -1.9 | -17.9 | -3.9 | -6.3 | -17.8 | +32.1 |
| 2024 | +3.5 | -0.3 | -20.7 | -19.9 | -0.9 | +5.6 | +9.6 | -13.2 | -15.5 | +0.3 | +33.6 | -28.6 |
| 2025 | +1.2 | +0.9 | -28.1 | +13.8 | +14.5 | -3.7 | -1.8 | +38.3 | +34.3 | +21.1 | +33.0 | +18.0 |
| 2026 | +2.3 | -13.3 | -2.5 | +16.8 | +4.1 | +8.4 | +5.2 | -4.2 | -20.3 |



